The latest announcement is out from Helix BioPharma ( (TSE:HBP) ).
Helix BioPharma Corp. has strengthened its leadership team by appointing three renowned experts in oncology and drug development. These strategic hires are aimed at advancing Helix’s clinical development and discovery strategies, particularly in enhancing the efficacy of immune-oncology therapies and developing next-generation targeted therapies. The new appointments are expected to significantly impact Helix’s operations and bolster its position in the oncology industry.
More about Helix BioPharma
Helix BioPharma Corp. is a clinical-stage oncology company focused on developing innovative therapies for hard-to-treat cancers. The company specializes in antibody-enzyme conjugates and antibody-drug conjugates, targeting non-small cell lung cancer and other solid tumors.
YTD Price Performance: -1.12%
Average Trading Volume: 2,619
Technical Sentiment Consensus Rating: Buy
Current Market Cap: C$46.66M
For detailed information about HBP stock, go to TipRanks’ Stock Analysis page.